Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Thursday, Marketbeat Ratings reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.
A number of other analysts also recently weighed in on CNTB. Oppenheimer reduced their target price on shares of Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, September 22nd. Wall Street Zen upgraded shares of Connect Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. Piper Sandler began coverage on shares of Connect Biopharma in a report on Friday, June 26th. They issued an “overweight” rating and a $7.00 target price on the stock. Finally, BTIG Research reduced their target price on shares of Connect Biopharma to $5.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.14.
View Our Latest Analysis on Connect Biopharma
Connect Biopharma Price Performance
Connect Biopharma (NASDAQ:CNTB – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. The business had revenue of $2.75 million during the quarter, compared to the consensus estimate of $0.74 million. As a group, equities analysts predict that Connect Biopharma will post -1.09 earnings per share for the current year.
Institutional Investors Weigh In On Connect Biopharma
Several hedge funds have recently modified their holdings of CNTB. Bank of America Corp DE purchased a new stake in shares of Connect Biopharma in the 1st quarter worth approximately $41,000. Simplify Asset Management Inc. purchased a new stake in shares of Connect Biopharma in the 1st quarter worth approximately $135,000. Richmond Brothers Inc. purchased a new stake in shares of Connect Biopharma in the 4th quarter worth approximately $489,000. Knott David M Jr lifted its position in shares of Connect Biopharma by 93.9% in the 1st quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after purchasing an additional 187,835 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Connect Biopharma in the 1st quarter worth approximately $1,945,000. Hedge funds and other institutional investors own 58.72% of the company’s stock.
Connect Biopharma Company Profile
Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.
Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.
Read More
- Five stocks we like better than Connect Biopharma
- This Space ETF Offers SpaceX Exposure—But Investors Are Paying for the Volatilit
- Does Lemonade’s Growth Signal Profits Ahead?
- These 3 ETFs Could Benefit From the Parts of Inflation That Won’t Go Away
- Why Light Is the New AI Bottleneck—And 3 Photonics Stocks to Play It
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
